Our fixed C-arm portfolio with procedural intelligence allows you to standardize every step of your TAVI workflow, so that you can ensure optimal outcomes for every patient.
TAVI cases in high and intermediate risk patients
Because cardiac surgeons encounter different patient risk groups, precautions are required to prevent complications and ensure optimal placement. Our Hybrid OR solutions enable you to establish standardized workflows, so that you can treat every patient the same way.
TAVI in the Hybrid ORPerfecting transcatheter valve replacement with procedural intelligence
Procedural intelligence changes TAVI treatment
Our fixed C-arms with procedural intelligence help you standardize your workflows and improve valve positioning. Intraoperative guidance software provides assistance throughout your TAVI procedures. With intelligent optimization of image quality and dose based on patient size and material in scope, along with automated C-arm positioning, treatment is greatly simplified. You can also standardize every workflow step thanks to TAVI Case Flow: select custom parameters for every procedure step just one time and then let the system set them automatically in the future.
Discover our TAVI workflow
Our assisted workflow for TAVI allows you to focus on the valve implantation itself. The software tools are easy to use, and the imaging system consistently provides the right images at the lowest reasonable dose.
Hear what our customers are saying
With multimodal imaging, innovative imaging chains, image fusion and different post-processing technologies in one system, we can manage more complex cases faster and less invasively.
Review the clinical evidence
Minimally invasive treatment with transcatheter aortic valve implantation permits minimally invasive treatment of patients with severe symptomatic aortic stenosis. Here are some of the key benefits you stand to gain by using our imaging systems equipped with procedural intelligence.
Impact on patient
Studies show that the absence of paravalvular leaks are linked to better 3-year survival rates1. Since our workflow optimizes valve positioning, it helps to improve outcomes.
See how TAVI patients can benefit
For patients with symptomatic aortic stenosis, TAVI represents an important treatment option that could improve their quality of life compared to open surgery2. Research shows that the procedure generally results in fewer difficulties and complications than open surgery. Patient outcomes within a year following TAVI treatment are favorable in over 60% of cases, permitting patients to experience reasonable quality of life.3,4
Our Hybrid OR imaging solutions
Avez-vous jugé cette information utile?
The statements by Siemens' customers described herein are based on results that were achieved in the customer's unique setting. Since there is no “typical” hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.
The statements with footnotes in this document are based on a result of the quoted clinical study that evaluates the procedure. The results are not generated with the actual product version. It is expected, that the actual product version has similar or improved functionality to support the evaluated procedure.
Some/All of the features and products described herein may not be available in the United States or other countries.
1
Susheel K. Kodali et al., “Two-Year Outcomes After Transcatheter or Surgical Aortic-Valve Replacement,”New England Journal of Medicine 366, no. 18 (2012): 1686–95, http://doi.org/10.1056/NEJMoa1200384.
2
Cristina Ciuca et al., “Cognitive and Quality of Life Trajectory after either Surgical or Transcatheter Aortic Valve Replacement in High-Risk Patients,” Giornale italiano di cardiologia 17, no. 12 Suppl 1 (2016): 15–21, http://doi.org/10.1714/2613.26898.
3
Suzanne J. Baron et al., “Health Status Benefits of Transcatheter vs. Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk: Results from the PARTNER 2 Randomized Clinical Trial,” JAMA Cardiology 2, no. 8 (2017): 837–845, http://doi.org/10.1001/jamacardio.2017.2039.
4
Suzanne V. Arnold et al., “Health Status After Transcatheter or Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis at Increased Surgical Risk: Results from the CoreValve US Pivotal Trial,” JACC: Cardiovascular Interventions 8, no. 9 (2015): 1207–1217, http://doi.org/10.1016/j.jcin.2015.04.018.